These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 6448349)

  • 1. Increased TRH content of the basal ganglia in Huntington's disease.
    Spindel ER; Wurtman RJ; Bird ED
    N Engl J Med; 1980 Nov; 303(21):1235-6. PubMed ID: 6448349
    [No Abstract]   [Full Text] [Related]  

  • 2. Beta-adrenergic receptor subtypes in the basal ganglia of patients with Huntington's chorea and Parkinson's disease.
    Waeber C; Rigo M; Chinaglia G; Probst A; Palacios JM
    Synapse; 1991 Aug; 8(4):270-80. PubMed ID: 1656540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationships of aging changes in the basal ganglia to manifestations of Huntington's chorea.
    Finch CE
    Ann Neurol; 1980 May; 7(5):406-11. PubMed ID: 6446874
    [No Abstract]   [Full Text] [Related]  

  • 4. Recent developments in Parkinson's disease and Huntington's chorea.
    Barbeau A
    Int J Neurol; 1976; 11(1):17-27. PubMed ID: 138661
    [No Abstract]   [Full Text] [Related]  

  • 5. Corticotropin-releasing hormone (CRH) is decreased in the basal ganglia in Huntington's disease.
    De Souza EB; Whitehouse PJ; Folstein SE; Price DL; Vale WW
    Brain Res; 1987 Dec; 437(2):355-9. PubMed ID: 2893655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoamine transmitters and their metabolites in the basal ganglia of Huntington's disease and control postmortem brain.
    Walsh FX; Bird ED; Stevens TJ
    Adv Neurol; 1982; 35():165-9. PubMed ID: 6183949
    [No Abstract]   [Full Text] [Related]  

  • 7. Neurotensin receptor binding levels in basal ganglia are not altered in Huntington's chorea or schizophrenia.
    Palacios JM; Chinaglia G; Rigo M; Ulrich J; Probst A
    Synapse; 1991 Feb; 7(2):114-22. PubMed ID: 1672780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Huntington's disease: modeling the gait disorder and proposing novel treatments.
    Banaie M; Sarbaz Y; Gharibzadeh S; Towhidkhah F
    J Theor Biol; 2008 Sep; 254(2):361-7. PubMed ID: 18621402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction in cholecystokinin-like immunoreactivity in the basal ganglia in Huntington's disease.
    Emson PC; Rehfeld JF; Langevin H; Rossor M
    Brain Res; 1980 Oct; 198(2):497-500. PubMed ID: 6447532
    [No Abstract]   [Full Text] [Related]  

  • 10. Cholecystokinin receptors are decreased in basal ganglia and cerebral cortex of Huntington's disease.
    Hays SE; Goodwin FK; Paul SM
    Brain Res; 1981 Nov; 225(2):452-6. PubMed ID: 6272931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Huntington's chorea. Deficiency of gamma-aminobutyric acid in brain.
    Perry TL; Hansen S; Kloster M
    N Engl J Med; 1973 Feb; 288(7):337-42. PubMed ID: 4345566
    [No Abstract]   [Full Text] [Related]  

  • 12. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia.
    Browne SE; Bowling AC; MacGarvey U; Baik MJ; Berger SC; Muqit MM; Bird ED; Beal MF
    Ann Neurol; 1997 May; 41(5):646-53. PubMed ID: 9153527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Saccadic eye movements in extrapyramidal disorders and particularly in Huntington's disease].
    Roig C
    Neurologia; 2001 Feb; 16(2):57-62. PubMed ID: 11257930
    [No Abstract]   [Full Text] [Related]  

  • 14. MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntingon's disease.
    Bartzokis G; Tishler TA
    Cell Mol Biol (Noisy-le-grand); 2000 Jun; 46(4):821-33. PubMed ID: 10875443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuropeptides in neurological disease.
    Beal MF; Martin JB
    Ann Neurol; 1986 Nov; 20(5):547-65. PubMed ID: 2947536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The distribution of GABAA-benzodiazepine receptors in the basal ganglia in Huntington's disease and in the quinolinic acid-lesioned rat.
    Faull RL; Waldvogel HJ; Nicholson LF; Synek BJ
    Prog Brain Res; 1993; 99():105-23. PubMed ID: 8108544
    [No Abstract]   [Full Text] [Related]  

  • 17. Regional brain concentrations of neuropeptides in Huntington's chorea and schizophrenia.
    Nemeroff CB; Youngblood WW; Manberg PJ; Prange AJ; Kizer JS
    Science; 1983 Sep; 221(4614):972-5. PubMed ID: 6136092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Localization of releasing hormones in the human brain.
    Koch Y; Okon E
    Int Rev Exp Pathol; 1979; 19():45-62. PubMed ID: 156704
    [No Abstract]   [Full Text] [Related]  

  • 19. [The molecular bases of Huntington's disease: the role played by oxidative stress].
    Tasset I; Sánchez F; Túnez I
    Rev Neurol; 2009 Oct 16-31; 49(8):424-9. PubMed ID: 19816846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postmortem studies of peptides in Alzheimer's disease and Huntington's disease.
    Rossor M; Emson P; Dawbarn D; Dockray G; Mountjoy C; Roth M
    Res Publ Assoc Res Nerv Ment Dis; 1986; 64():259-77. PubMed ID: 2425405
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.